The rule-in / rule-out
testing platform that
greatly improves
risk stratification of
thyroid nodules

Combination Testing

The combination testing platform allows ThyGeNEXT and ThyraMIR to work together, providing accurate reclassification for an 85% reduction in unnecessary surgeries.1

Markers That Matter

Strategically Designed Panel for the Optimal Management of Thyroid Nodules. And now, newly added TERT and ALK mutations can reliably help to predict aggressive biological features of thyroid cancer.

Performance Matters

ThyGeNEXT + ThyraMIR Combination Testing Performance1
50 %
Sensitivity
50 %
Specificity
50 %
NPV
40 %
PPV

Flexibility Matters

Interpace Diagnostics is the only company that offers:

Testing of fresh FNA samples or direct smears/ThinPrep® slides

No special shipping or refrigeration requirements

Mutation panel + miRNA expression classifier

Modal Title

News

References

  1. Labourier, et al, Journal Clinical Endocrinology Metabolism 100: 2743, 2015
  2. Xing M et al., BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence, Journal of Clinical Oncology 2014
Scroll to Top